Want to see AU:TRP full AI Analyst Report?
Top Page
Tissue Repair Ltd
(Sydney:TRP)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.10
▼(-74.47% Downside)
Action:Reiterated
Date:05/01/26
The score is weighed down primarily by sustained losses and negative free cash flow with rising burn and declining equity, despite strong recent revenue growth and a debt-free balance sheet. Technicals add further pressure as the stock trades below major moving averages with negative MACD, while valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Revenue acceleration & gross margins
Sharp 2025 revenue acceleration combined with sustained very high gross margins signals meaningful product-market traction and pricing power. This improves structural revenue visibility and supports long-term margin sustainability if cost discipline continues and scale is maintained.
Negative Factors
Persistent negative cash flow
Consistently negative operating and free cash flows, with FCF worsening year-over-year, indicate ongoing cash burn and runway pressure. Over months, this elevates funding and dilution risk and constrains the firm's ability to fund commercialization or scale without external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue acceleration & gross margins
Sharp 2025 revenue acceleration combined with sustained very high gross margins signals meaningful product-market traction and pricing power. This improves structural revenue visibility and supports long-term margin sustainability if cost discipline continues and scale is maintained.
Read all positive factors
Tissue Repair Ltd (TRP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$6.05M
Dividend YieldN/A
Average Volume (3M)93.72K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue Growth82.28%
EPS Growth13.33%
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$7.18M
Tissue Repair Ltd Business Overview & Revenue Model
Company Description
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing reco...
How the Company Makes Money
null...
Tissue Repair Ltd Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.63M | 152.24K | 3.08K | 171.92K | 152.64K |
| Gross Profit | 2.63M | 150.51K | 428.00 | 170.21K | 152.64K |
| EBITDA | -4.72M | -6.51M | -5.14M | -7.01M | -189.44K |
| Net Income | -4.24M | -4.14M | -4.17M | -6.84M | -915.23K |
Balance Sheet | |||||
| Total Assets | 14.57M | 19.39M | 22.38M | 25.90M | 27.61M |
| Cash, Cash Equivalents and Short-Term Investments | 12.32M | 16.44M | 21.40M | 25.46M | 27.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 7.50M |
| Total Liabilities | 662.53K | 1.35M | 497.35K | 559.64K | 536.00K |
| Stockholders Equity | 13.91M | 18.04M | 21.88M | 25.34M | 27.07M |
Cash Flow | |||||
| Free Cash Flow | -4.12M | -4.95M | -4.26M | -3.97M | -852.89K |
| Operating Cash Flow | -3.70M | -4.95M | -4.26M | -3.97M | -852.89K |
| Investing Cash Flow | -421.67K | -3.35K | -2.24K | -3.92K | 5.00K |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 21.36M | 7.46M |
Tissue Repair Ltd Technical Analysis
Negative
0.38
Price Trends
0.12
Negative
0.14
Negative
0.23
Negative
Market Momentum
>-0.01
Negative
37.94
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.12, and above the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 37.94 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRP.
Tissue Repair Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$2.53B | -21.27 | -14.02% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$6.27M | -2.07 | -211.88% | ― | 250.37% | 71.29% | |
46 Neutral | AU$11.75M | -1.72 | -218.76% | ― | 76.94% | 42.95% | |
45 Neutral | AU$51.95M | -0.41 | -131.13% | ― | 2086.71% | -116.20% | |
44 Neutral | AU$6.05M | -1.57 | -29.91% | ― | 82.28% | 13.33% | |
41 Neutral | AU$197.38M | -14.24 | -44.80% | ― | 49.03% | -232.68% |
* Healthcare Sector Average
AU:TRP
Tissue Repair Ltd
0.10
-0.08
-44.44%
AU:ACR
Acrux
0.01
>-0.01
-33.33%
AU:MSB
Mesoblast Limited
1.96
0.11
6.25%
AU:OCC
Orthocell Ltd
0.73
-0.54
-42.46%
AU:CMB
Regeneus Ltd.
0.43
0.22
104.76%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.29
-93.87%
Tissue Repair Ltd Corporate Events
Tissue Repair Ramps Up TR987 Trial as TR Pro+ Sales and Device Strategy Advance
Apr 30, 2026
Tissue Repair reported accelerated recruitment in its U.S. Phase 3 trial of TR987 for chronic wounds, with 64 patients randomised and a target of about 100 patients by September 2026 to enable interim analysis. The company is also advancing a devi...
Tissue Repair Discloses New Director Peter Scutt’s Equity Stake
Apr 20, 2026
Tissue Repair Ltd has appointed Peter Scutt as a director effective 20 April 2026, and disclosed his initial interests in the company’s securities in accordance with ASX listing rules. The filing shows Scutt holds a substantial package of un...
Tissue Repair Appoints Co-Founder Peter Scutt as Executive Director to Drive Market Expansion
Apr 20, 2026
Tissue Repair Limited has appointed co-founder Peter Scutt as an Executive Director, effective 20 April 2026, and engaged him under a consultancy agreement to support the CEO on strategy for domestic and international market entry and distribution...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.